A 24-month head-to-head retrospective study of denosumab versus intravenous ibandronate: Study design
Latest Information Update: 28 Nov 2014
Price :
$35 *
At a glance
- Drugs Denosumab (Primary) ; Ibandronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms DEVIDE
- 15 May 2014 New trial record